OMIX002219

1Summary
Title Safety, Tolerability, and PK of Single and Multiple Doses of Aficamten in Healthy Chinese Subjects
Description This is a double-blind, randomized, placebo-controlled, Phase 1 study in healthy Chinese adult subjects to evaluate the safety, tolerability and PK of SAD and MD of CK-3773274. Approximately 8 healthy Chinese subjects will receive CK-3773274 10mg or placebo in the SAD 10mg cohort A. At least 5 days after the last subject's administration in the cohort A, approximately 8 subjects will be enrolled into the SAD 20mg cohort B. At least 5 days after the last subject's administration in the cohort B, approximately 12 subjects will be enrolled into MD 5mg cohort D, respectively. Subjects will be remained in clinical research unit (CRU) during the entire dosing period and the following 4 days post-dose for SAD, and 3 days post-dose for MD.
Organism Homo sapiens
Data Type Clinical Research data
Data Accessibility Controlled-access
BioProject PRJCA012813
Release Date 2024-12-31
Submitter Xiaohong Han (hanxiaohong@pumch.cn)
Organization Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Submission Date 2022-10-27
2Files & Download

HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).

File ID File Title Number/Samples File Type File Size File Suffix Download
OMIX002219-21 01_Clinical Data 1 Clinical Research data 939.6 KB pdf Controlled
3Relevant Publications
Paper Title Journal Name Publish Time Accession Citing Type

View All Released Data of OMIX